scholarly journals Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis

PLoS ONE ◽  
2018 ◽  
Vol 13 (1) ◽  
pp. e0191455 ◽  
Author(s):  
Aimee R. Hayes ◽  
Daniel Brungs ◽  
Nick Pavlakis
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
High Risk ◽  
Bone Metastases ◽  
Metastatic Prostate Cancer ◽  
Meta Analysis

Prognostic Impact of C-Reactive Protein in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis

2014 ◽  
Vol 37 (12) ◽  
pp. 772-776 ◽  
Author(s):  
Pedro Rocha ◽  
Charity J. Morgan ◽  
Arnoud J. Templeton ◽  
Gregory R. Pond ◽  
Gurudatta Naik ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Metastatic Prostate Cancer ◽  
Meta Analysis ◽  
Prognostic Impact ◽  
C Reactive Protein ◽  
Reactive Protein

scholarly journals The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis

2018 ◽  
Vol Volume 11 ◽  
pp. 9061-9070 ◽  
Author(s):  
Junru Chen ◽  
Xingming Zhang ◽  
Guangxi Sun ◽  
Jinge Zhao ◽  
Jiandong Liu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
High Risk ◽  
Meta Analysis ◽  
High Risk Prostate Cancer ◽  
Additional Chemotherapy ◽  
Risk Prostate Cancer

scholarly journals Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

2021 ◽  
Author(s):  
Mike Wenzel ◽  
Luigi Nocera ◽  
Claudia Collà Ruvolo ◽  
Christoph Würnschimmel ◽  
Zhe Tian ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Overall Survival ◽  
High Risk ◽  
Meta Analysis ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Pubmed Search ◽  
Grade 3 ◽  
Meta Analyses

Abstract Background The most recent overall survival (OS) and adverse event (AE) data have not been compared for the three guideline-recommended high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) treatment alternatives. Methods We performed a systematic review and network meta-analysis focusing on OS and AE according to the most recent apalutamide, enzalutamide, and darolutamide reports. We systematically examined and compared apalutamide vs. enzalutamide vs. darolutamide efficacy and toxicity, relative to ADT according to PRISMA. We relied on PubMed search for most recent reports addressing prospective randomized trials with proven predefined OS benefit, relative to ADT: SPARTAN, PROSPER, and ARAMIS. OS represented the primary outcome and AEs represented secondary outcomes. Results Overall, data originated from 4117 observations made within the three trials that were analyzed. Regarding OS benefit relative to ADT, darolutamide ranked first, followed by enzalutamide and apalutamide, in that order. In the subgroup of PSA-doubling time (PSA-DT) ≤ 6 months patients, enzalutamide ranked first, followed by darolutamide and apalutamide in that order. Conversely, in the subgroup of PSA-DT 6–10 months patients, darolutamide ranked first, followed by apalutamide and enzalutamide, in that order. Regarding grade 3+ AEs, darolutamide was most favorable, followed by enzalutamide and apalutamide, in that order. Conclusion The current network meta-analysis suggests the highest OS efficacy and lowest grade 3+ toxicity for darolutamide. However, in the PSA-DT ≤ 6 months subgroup, the highest efficacy was recorded for enzalutamide. It is noteworthy that study design, study population, and follow-up duration represent some of the potentially critical differences that distinguish between the three studies and remained statistically unaccounted for using the network meta-analysis methodology. Those differences should be strongly considered in the interpretation of the current and any network meta-analyses.

Cytoreductive radical prostatectomy versus systemic therapy and radiation therapy in metastatic prostate cancer: A systematic review and meta-analysis

2021 ◽  
pp. 039156032110366
Author(s):  
Hamidreza Shemshaki ◽  
Said Abdallah Al-Mamari ◽  
Ishfaq Ahmed Geelani ◽  
Santosh Kumar
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Radiation Therapy ◽  
Radical Prostatectomy ◽  
Systemic Therapy ◽  
Metastatic Prostate Cancer ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Original Research ◽  
The Cochrane Library

Cytoreductive prostatectomy had gained a lot of interest in treatment of metastatic prostate cancer (mPCa) but this treatment approach is still in the experimental phase. This systematic review and meta-analysis was conducted to shed light on the merits of cytoreductive radical prostatectomy compared to systemic and radiation therapy in treatment of mPCa. In February 2021, summary data from 12 original research papers covering 100,973 patients is abstracted. PubMed/Medline, Scopus, Google Scholar, EMBASE, and the Cochrane Library were all reviewed and 12 publications were chosen for inclusion. The evaluated outcomes were 1-, 3-, and 5-year Cancer-Specific (CSS) and overall survival (OS) rates. Cytoreductive radical prostatectomy had significantly higher survival rate for 1-year (OR: 3.03; 95% CI: 2.30–3.98; p < 0.001), 3-year (OR: 2.47; 95% CI: 2.14–3.51; p < 0.001), and 5-year CSS rates (OR: 2.90; 95% CI: 2.10–4.01; p < 0.001) than systemic therapy in mPCa. Higher significant rates of 1-year (OR: 2.35; 95% CI: 1.65–3.36; p < 0.001), three-year (OR: 2.25; 95% CI: 1.96–2.60; p < 0.001), and 5-year OS rates (OR: 2.54; 95% CI: 2.10–3.08; p < 0.001) were also detected for cytoreductive radical prostatectomy compared to systemic therapy. There were no significant differences in 1-year (OR: 1.21; 95% CI: 0.88–1.66; p = 0.25), 3-year (OR: 1.21; 95% CI: 0.92–1.59; p = 0.18), and 5-year CSS rates (OR: 0.91; 95% CI: 0.58–1.42; p = 0.67) between cytoreductive radical prostatectomy and radiation in mPCa patients. Also, no significant differences in 1-year (OR: 1.06; 95% CI: 0.77–1.47; p = 0.71), 3-year (OR: 0.83; 95% CI: 0.60–1.14; p = 0.25), and 5-year OS rates (OR: 1.84; 95% CI: 0.76–4.45; p = 0.18) were detected between cytoreductive radical prostatectomy and radiation therapy. Cytoreductive radical prostatectomy had significantly higher 1-, 3-, and 5-year CSS and OS rates compared to systemic therapy. Comparable CSS and OS rates were found between cytoreductive radical prostatectomy and radiation therapy.

Sign in / Sign up

Export Citation Format

Share Document